Benzinga··Bamboo WorksVivaVision Races to Complete Hong Kong IPO as Cash Runway Narrows
VivaVision Biotech rushes Hong Kong IPO as cash reserves dwindle to $5.2 million against $6.3 million quarterly burn rate. Two late-stage eye disease candidates drive investor appeal.
AMGNABTcash burnclinical trials